BioCentury
ARTICLE | Strategy

Biofrontera’s chemical attraction

July 21, 2003 7:00 AM UTC

When neurological company Biofrontera Pharmaceuticals Holding AG announced plans to merge with Kiadis B.V., the attraction of Kiadis was its chemistry and screening technology, which Biofrontera said would help it develop compounds more rapidly. That proposed deal hasn’t stopped Biofrontera from acquiring additional chemical expertise by buying the assets of drug discovery company bioLeads GmbH. According to Biofrontera, Kiadis and bioLeads provide complementary technologies. Indeed, Biofrontera said it will continue to look for additional acquisitions to help round out its value chain, which is short on products.

bioLeads, which already had an alliance with Biofrontera to discover and develop novel CNS compounds, became insolvent in March. Biofrontera will incorporate the assets into a wholly owned subsidiary, Biofrontera Discovery GmbH. The acquisition was financed by Heidelberg Innovation, 3i,TMK and Leventure, which put in an undisclosed amount of money (see B3). ...